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Summary
Mantle cell lymphoma (MCL) patients have poor prognosis, due to development of chemo-
resistance in relapsing patients. Therefore, despite the features of indolent lymphoma at 
presentation, consolidation and/or maintenance strategies to achieve minimal tumor burden 
and postpone subsequent relapses remain the standard of care. 
In the retrospective analysis of Polish Lymphoma Research Group (PLRG), post-induction 
strategies were assessed in 355 MCL patients. Those in complete or partial remission (CR or 
PR) after induction regimen (n = 263, 74.08%) were consolidated with autologous stem cell 
transplantation (ASCT) (n = 71, 20%) or radioimmunotherapy (RIT, n = 37, 10.42%), subjected to 
rituximab maintenance (MR, n = 17, 4.79%) or had none post-induction treatment (NPI, n = 138, 
38.87%). Responses to therapy, progression and overall survival (PFS and OS) were compared.
CR after induction was significantly increased by consolidation strategies, from 68% to 95% in 
ASCT and from 43% to 90% in RIT cohort. Median PFS in patients subjected to ASCT and RIT 
was significantly higher compared to NPI group (2.3, 3.8 and 1.8 years respectively, p <0.05). 
Consolidation strategies also prolonged median OS (not reached in ASCT, 7.3 in RIT and 4 years 
in NPI cohort,  p <0.005 ). 
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INTRODUCTION
Mantle cell lymphoma (MCL) is a subtype of the mature 
B cell neoplasm with annual incidence approximately 
1–2 cases/100 000/year. It has an aggressive clinical 
course due to high relapse rate and early development 
of chemoresistance [16]. The initial treatment depends 
on disease related risk factors, patient performance 
status and comorbidities  [4, 5]. Most centers use the 
Mantle Cell Lymphoma International Prognostic Index 
(MIPI) incorporating patient’s age, lactate dehydroge-
nase (LDH), performance status and white blood cell 
count (WBC) [9]. In one of the studies, overall survival 
(OS) varied depending on the MIPI score with 5-year OS 
of 60% for low-risk patients, and median OS of 51 and 
29 months for the intermediate and high-risk patients 
respectively [23].
The adequate choice of the first-line therapy depends 
on patient age, performance status and comorbidities. 
In younger, fit patients an intensive frontline immu-
nochemotherapy in corporating cycles with high-dose 
cytarabine (HDAC), followed by ASCT consolidation, 
increases response rates and prolongs the time to treat-
ment failure and overall survival [6, 8, 12]. The three 
most commonly used regimens include rituximab, 
cyclophosphamide, doxorubicin, vincristine, and pred-
nisone (R-CHOP), which were amended with rituximab, 
dexamethasone, cytarabine and a platinum derivative 
(R-DHAP), based on European Mantle Cell Lymphoma 
Network (EMCLN) experience  [8], dose-intensified 
R-CHOP (R maxi-CHOP) altering with R-HDAC, described 
by Nordic Lymphoma Group [7, 12] and intensive high-
dose therapy as hyperfractionated cyclophosphamide, 
vincristine, doxorubicin and dexamethasone alternat-
ing with a high-dose methothrexat/cytarabine (HCVAD/
MA), developed at the MD Anderson Cancer Center 
(MDACC) [1, 19]. The less intense the induction regimen, 
the greater the role of ASCT consolidation; therefore, it 
should be considered in all patients treated with R-CHOP 
as well [10, 18]. There are no differences between the 
efficacy of different transplant conditioning regimens, 
in particular between high dose chemotherapy and 
TBI (total body irradiation) [17, 22]. Rituximab mainte-
nance following high-dose regimens and ASCT has been 
recently recommended after the results of LyMA trial 
were published [14]. 
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ASCT – autologous stem cell transplantation, BEAM – carmustine, etoposide, cytarabine and mel-
phalan regimen, BR – rituximab plus bendamustine, BTK – Bruton tyrosine kinase, CR – complete 
remission, CVP – cyclophosphamide, vincristine and prednisone, GELTAMO – Grupo Español de 
Linfomas y Transplante Autólogo de Médula Ósea, HCVAD/MA – hyperfractionated cyclophospha-
mide, vincristine, doxorubicin and dexamethasone alternating with high-dose methothrexat/cyta-
rabine, HDAC – high-dose cytarabine, LDH – lactate dehydrogenase, MCL – mantle cell lymphoma, 
MDACC – MD Anderson Cancer Center, MIPI – Mantle Cell Lymphoma International Prognostic 
Index, MRD – minimal residual disease, NPI – none post-induction treatment, OS – overall survival, 
PFS – progression free survival, PLRG – Polish Lymphoma Research Group, PR – partial remission, 
R-CHOP – rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-DHAP – 
rituximab, dexamethasone, cytarabine and a platinum derivative, R-FC – rituximab, fludarabine 
and cyclophosphamide, R-maxiCHOP – dose-intensified R-CHOP, RIT – radioimmunotherapy, 
RM – rituximab maintenance, TBI – total body irradiation, WBC – white blood cell count.
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classification. The disease response was determined 
according to Cheson criteria revised in Lugano  [3]. 
The complete assessment was performed after com-
pleting induction therapy, and later repeated every 
6 months during the follow-up period. After a 5-year 
follow-up, patients were still under control annually, 
during which they were given physical examinations 
and blood tests. The median follow-up period was 5.4 
years (range 0–11 years). 
Patients were classified into 5 subgroups according 
to the response to induction therapy and the type 
of post-induction treatment. The first four cohorts 
consisted of patients achieving CR or PR after induc-
tion regimen (n = 263, 74.08%) with post-induction 
ap•proaches as follow: 
• consolidation with ASCT (n = 71, 20%), 
• consolidation with RIT (n = 37, 10.42%), 
• rituximab maintenance (n = 17, 4.79%), 
• no post-induction treatment (NPI, n = 138, 38.87%). 
The fifth subgroup consists of primary refractory 
patients, where no consolidation or maintenance could 
have been implemented. The retrospective design of 
the study did not allow for an intention to treat analy-
sis (IIT), so those patients were not evaluated any fur-
ther. 
Older patients, i.e. after the median age of 65 years, are 
commonly treated with R-CHOPor purine analoque-
based regimen  [13, 15, 20]. Rituximab maintenance 
proved to increase both PFS and OS, especially in 
R-CHOP treated patients. It seemed to be less effective 
due to adverse reactions, after induction therapy based 
on purine analoques [19].
Radioimmunotherapy with ibritumomabtiuxetan 
(a monoclonal antibody directed against the CD20 com-
bined with tiuxetan chelating radioactive Yttrium-90, 
RIT) may be an alternative consolidation approach for 
elderly patients with comorbidities, not eligible for 
a transplant. In a retrospective analysis of PLRG the out-
come and results of initial treatment followed or not 
by post-induction consolidation (ASCT, RIT or MR) was 
compared in responding MCL patients.
MATERIALS AND METHODS
Study cohort, oncological status and treatment
355 MCL, treatment-naive patients were diagnosed, 
treated and retrospectively evaluated in 12 PLRG 
centers between 1997 and 2014. Diagnosis of MCL was 
confirmed by histopathology with adequate cyto-
chemical stains, including the presence of cyclin D1 
over expression. Data on Ki-67 expression was not 
available. MIPI was calculated at the time of diagno-
sis based on age, performance status (Eastern Coop-
erative Oncology Group – ECOG), LDH activity, and 
WBC [9]. Staging was assessed according to Ann Arbor 
Table 1. Characteristics of patients divided in 5 subgroups
Parameter 1 2 3 4 5 1-5 p value p value
ASCT
n (%)
RIT
n (%)
MR
n (%)
≥PR, NPI
n (%)
<PR
n (%)
All
n (%)
between 
1st and 4th 
subgroup
between 
2nd 
and 4th 
subgroup
n 71 37 17 138 92 355
Age - median (range)
53
(31–78)
61
(38–78)
58
(37–77)
62
(32–79)
67
(37–84)
60
(31–84)
<0.05 NS
Sex (male) 53 (75) 29 (78) 10 (59) 92 (67) 61 (66) 245 (69) NS NS
ECOG >1 4 (6) 6 (16) 0 (0) 22 (16) 29 (32) 61 (17) NS NS
Clinical stage III-IV 69 (97) 35 (95) 17 (100) 133 (96) 91 (99) 345 (97) NS NS
B symptoms 41 (58) 18 (49) 5 (29) 73 (53) 65 (71) 202 (57) NS NS
WBC [G/l] - median (range)
10
(2–13.6)
7,3
(3.1–34)
7 (4–41) 8 (1.5–96)
10,8
(1.2–28)
8,7
(1.2–96)
NS NS
LDH activity (increased) 34 (48) 15 (41) 3 (18) 59 (43) 57 (62) 168 (47) NS NS
MIPI - low ris 40 (56) 14 (38) 8 (47) 40 (29) 15 (16) 117 (33) <0.05 NS
MIPI - intermediate risk 15 (21) 12 (32) 7 (41) 46 (33) 21 (23) 101 (28) <0.05 NS
MIPI - high risk 10 (14) 11 (30) 1 (6) 38 (28) 51 (55) 111 (31) <0.05 NS
MIPI - missing data 6 (8) 0 1 (6) 14 (10) 5 (5) 26 (7) <0.05 NS
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patients presented the advanced stage of disease (III–IV). 
There were no significant differences in the character-
istics between patients with radioimmunotherapy con-
solidation, rituximab maintenance and those with with 
no post-induction therapy. The transplanted patients 
have lower median age and lower MIPI score (p <0.05). 
Patients who were refractory to first line treatment 
had the most negative predictive factors and unfavora-
ble prognosis with median survival of approximately 7 
months. They were the oldest subgroup with the worst 
ECOG status and MIPI index, the highest rate of B symp-
toms and most increased LDH activity. 
The data on response rates after specific induction ther-
apies and median follow-up time is presented in Table 2. 
The most common regimen was CHOP (n = 157, 44.23%), 
followed by purine – analoque based (n = 44, 12.39%), 
maxi-CHOP/HDAC (n = 40, 11.27%), CVP(n = 33, 9.29%), 
HCVAD/MA (n = 14, 3.94%). The median number of 
administered cycles was 6 (range 1–10). Analysis focused 
on subgroups 1–2 and 4 comparing patients responding 
to induction therapy and excluded from subsequent 
survival analysis subgroup 3 (rituximab maintenance), 
because of relatively low number of patients.
Statistical analysis
Clinical characteristics were compared between treatment 
subgroups using the χ2 test for categoric variables and the 
t test for continuous variables. The main analyzed end-
points included PFS and OS. PFS was defined as the time 
from the date of diagnosis to disease progression, relapse, 
or the date the patient was last known to be alive. OS was 
measured from the date of diagnosis until death from any 
cause or the date of the last follow-up. PFS and OS were 
evaluated using the Kaplan-Meier method powered by log-
rank statistics. A p value of less than 0.05 was considered 
significant. Statistical analyses were performed using the 
Statistica software version 10 (Stat Soft, Kraków, Poland).
RESULTS
Patient characteristics
Patient characteristics and demographics comparing the 
five subgroups are shown in Table 1. The median age at 
diagnosis was 60 (range 31–84) with male/female ratio 
of 2.23. Patients subjected to ASCT were younger than 
patients in subgroups 2–4. The vast majority (97%) of 
Table 2. Induction first-line treatment of patients with mantle cell lymphoma divided in 5 subgroups
1 2 3 4 5 1-5 p value p value
ASCT RIT MR ≥PR, NPI SD and PD all
between 
1st and 4th 
cohort
between 
2nd and 4th 
cohort
n 71 37 17 138 92 355
Immunochemotherapy 
(with Rituximab)
61 (86) 22 (59) 16 (94) 82 (59) 28 (30) 209 (59) <0.05 NS
CHOP-like 23 (32) 27 (73) 5 (29) 70 (51) 32 (35) 157 (44)
Purine analogue-based 1 (1) 7 (19) 0 23 (17) 13 (14) 44 (12)
maxiCHOP/HDAC 23 (32) 0 3 (18) 11 (8) 3 (3) 40 (11) <0.05 NS
HCVAD/MA 5 (7) 2 (5) 0 5 (4) 2 (2) 14 (4)
CVP 3 (4) 1 (3) 0 9 (7) 20 (22) 33 (9)
Chl or GKS 0 0 0 1 (1) 12 (13) 13 (4)
Missing data 16 (23) 0 9 (53) 19 (14) 10 (11) 54 (15)
N of cycles Median (range) 6 (1–8) 5 (1–6) 6 (3–18) 6 (0–9) 3 (0–10) 6 (0–10) NS NS
CR after induction 48 (68) 16 (43) 10 (59) 71 (51) NA 145 (41) <0.05 NS
CR after consolidation 95% 90% N/A N/A N/A N/A
Follow-up (years) 
Median (range)
6.1(0.3–10.7) 6.2 (0.8–9)
5.5(1.1–
10.6)
5.1 
(0–10.6)
0.9 
(0–6.7)
5.4 
(0–11)
Median OS (years) Not reached 7.3 4 4 0.83 <0.05 <0.05
Median PFS (years) 2.25 3.75 1.83 1.83 0.5 <0.05 <0.05
Chl or GKS - chlorambucil or glicocorticoids
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DISCUSSION
Consolidation of frontline therapy MCL patients with 
ASCT became an undisputable standard of care after 
EMCLN trial performed in pre-rituximab era [6]. High 
dose therapy prolonged median PFS (3.7 years vs 1.6 
years in patients treated with interferon) without sig-
nificant differences in 3-year OS (83 vs 77%). Since most 
of the clinical trials and retrospective analyses focused 
on the choice of the best induction regimen, European 
“second generation” EMCLN randomized comparison 
between R-CHOP and R-CHOP/R-DHAP, both consoli-
dated by ASCT in 497 newly diagnosed MCL patients, was 
the first trial proving the efficacy of cytarabine-based 
induction regimen. It significantly prolonged time to 
treatment failure (median TTF 9.1 years vs 3.9 years in 
control group) and without evident overall survival ben-
efit at the time of analysis (projected OS at 5 years 76 vs 
69% respectively) [8]. In most publications, 5-year over-
all and progression-free survival rates were reported 
as 60–80% and 35–70%, respectively [6, 7, 8, 12, 23]. In 
this perspective, transplant results of MCL patients 
described in PLRG comparison do not look satisfactory, 
even considering the difference between the real-life 
experience and clinical trials. Although median OS was 
not reached after observation time exceeded 6 years, 
median PFS was only 2.25 years, which was at most com-
parable to I generation EMCLN trial. The MIPI score and 
risk factor distribution was typical for transplanted 
patients. The majority of the patients (86%) were treated 
with rituximab containing induction regimens, but only 
39% received intermediate dose cytarabine. Further 31 
patients received rituximab maintenance at the time 
of molecular relapse, which had a major impact on PFS 
analysis. Considering only clinical relapses, median PFS 
in the whole group increased from 2.25 to 4.1 years. 
Only 20% of MCL patients described in our analysis were 
consolidated with ASCT after first-line treatment. This 
confirms the limited accessibility of this procedure for 
selected patients (younger, with lower MIPI). The major-
Rituximab was administered in 59% patients (n = 209). 
It was least frequently used in refractory patients (n 
= 28, 30% of the cases), most commonly in ASCT and 
Rituximab maintenance cohort (86% and 94% respec-
tively). Forty-six patients (12.96%) received suboptimal 
induction consisting of cyclophosphamide, vincris-
tine andprednison (CVP), chlorambucil, or glicocor-
ticosteroids. Anthracycline and/or intermediate dose 
cytarabine containing regimens clearly increased the 
number of responding patients and CRs (Table 2). In 
ASCT cohort, 67% of patients underwent carmustine, 
etoposide, cytarabine and melphalan regimen (BEAM) 
and 33% received total body irradiation (TBI) with 
high-dose cyclophosphamide. 
Two hundred sixty-three patients (74.08%) responded 
to the induction treatment, 145 (40.8%) with CR. 
Ninety-two patients (25.9%) did not respond to ini-
tial therapy and were analyzed as a separate cohort to 
allow for a fair assessment of the role of post-induction 
strategies, possible only in responding patients. We did 
not draw any conclusions from rituximab maintenance 
cohort, as there were only 17 patients treated this way. 
CR after induction was significantly increased by con-
solidation strategies, from 68% to 95% in ASCT and 
from 43% to 90% in RIT cohort. Kaplan Meier analysis 
is presented on Figure 1 and 2. Median PFSin patients 
subjected to ASCT and RIT was significantly higher 
compared to NPI cohort (2.3, 3.8 and 1.8 years respec-
tively, p <0.05). Consolidation strategies also prolonged 
median overall survival (not reached in ASCT, 7.3 years 
in RIT and 4 years in cohort with no post induction 
therapy, p <0.005). 
During the study, 148 patients (41.7%) died: 119 (33.52%) 
due to relapsing/refractory MCL, 29 (8.17%) secondary 
to non-relapse events (infections 8–2, 25%, cardiotoxic-
ity 8-2.25%, myelodysplastic syndrome/acute myeloid 
leukemia 4–1.13%, multi-organ failure 2–0.56%, suicide 
1–0, 28%, unknown reason 4–1, 13%).
Fig. 1. Kaplan Mayer analysis – OS in subsequent cohorts Fig. 2. Kaplan Mayer analysis – PFS in subsequent cohorts
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nochemiotherapy  [13]. The R-CHOP with subsequent 
maintenance therapy with rituximab has shown the OS 
rates (4-year survival rate, 87%). At the time of analysis, 
it was not the standard of care in Poland; RM cohort was 
too small to draw any meaningful conclusions.
While in young patients consolidation with ASCT is an 
indisputable standard of care, in older patients ineligi-
ble for ASCT the choice of optimal therapy is still disput-
able. Furthermore, this may be changed in nearby future 
by Bruton tyrosine kinase (BTK) inhibitors. Both (ibru-
tinib, acalabrutinib) are registered for relapsed/refrac-
tory MCL [24, 25] and their potential role in the frontline 
therapy is being evaluated. Two randomized clinical tri-
als comparing efficacy of rituximab plus bendamustine 
(BR) followed by Rituximab maintenance with or with-
out BTK inhibitors are ongoing (SHINE, ACE-LY-308), 
the preliminary results of Ibrutinib trial should be 
announced in 2019. Interpretation of results may be dif-
ficult, as purine analoque-based immunochemotherapy 
with rituximab maintenance is not regarded as a stand-
ard of care, and rituximab, fludarabine and cyclophos-
phamide (R-FC) was inferior to R-CHOP in a randomized 
in EMCLN trial  [13]. Although both trials have PFS as 
a primary target, with an already established role of BTK 
inhibitors in relapsed MCL, only OS benefit could change 
the clinical practice in the I line therapy. 
In conclusion, taking into account the lower level of evi-
dence of retrospective studies, our findings confirm that 
in younger, selected patients with MCL the ASCT consol-
idation in first CR or PR provides satisfactory OS and PFS 
rates. In transplant-ineligible MCL patients in first CR or 
PR radioimmunotherapy as consolidation may be alter-
native to rituximab maintenance. Our results emphasize 
the necessity of post-induction approaches in all MCL 
patients, responding to the first line therapy.
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ity of patients are transplant-ineligible, due to advanced 
age, poor performance status or comorbidities. Mini-
mal residual disease (MRD) status is predictive of clin-
ical progression [18]; thus, alternative post-induction 
approaches should be recommended.
Radioimmunotherapy as an alternative method of consol-
idation, which can be relatively safe in patients who are 
transplant-ineligible, with increased risk of toxicity due 
to age or comorbidities. Complications after radioimmu-
notherapy are relatively delayed and are mainly related to 
prolonged cytopenias. They are feasible in most patients 
with response to first line treatment, with bone marrow 
infiltration of less than 10% and lymph node size less than 
2–3 cm. The efficacy of radioimmunotherapy with ibri-
tumomabtiuxetan as a consolidation in first line treat-
ment was demonstrated in 3 multicenter clinical trials, 
performed by: ECOG [21], Grupo Español de Linfomas y 
Transplante Autólogo de Médula Ósea (GELTAMO) [2], and 
PLRG [11]. In ECOG trial the intent-to-treat five-year OS 
was 73%. In GELTAMO four-year OS was 87% and failure 
free-survival 55%. In PLRG trial, 40% of patients consoli-
dated in CR did not progress within 8 years of observa-
tion. In our analysis, most of the patients subjected to 
radioimmunotherapy either participated in the PLRG 
MCL 04 clinical trial or were treated by the centers partic-
ipating in this trial; therefore, they do not present genu-
ine real-life data. The patients’ demographic MIPI and risk 
factors distribution were fully comparable to elderly MCL 
cohort, which were not submitted to any post-induction 
therapy (Table 1). Our data demonstrated the superiority 
of ibritumomabtiuxetan consolidation. It increased the 
CR rate from 43% to 90%. Both median PFS and median OS 
of patients subjected to RIT was significantly prolonged, 
compared to the cohort with no post induction therapy 
(3.75 vs 1.83 years and 7.3 vs 4.0 years respectively, p 
<0.05). One third of the patients consolidated with radi-
oimmunotherapy are in continuous remission, 8 years 
after the procedure. 
Rituximab maintenance is at present the standard of 
care in both elderly and transplanted patients. It sig-
nificantly improves PFS and OS after R-CHOP immu-
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